Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers

Abstract

The mitotic checkpoint is thought to be essential for ensuring accurate chromosome segregation by implementing mitotic delay in response to a spindle defect. To date, however, very little data has become available on the defects of the mitotic checkpoint in human cancer cells. In the present study, impaired mitotic checkpoint was found in four (44%) of nine human lung cancer cell lines. To our knowledge, this is the first demonstration of frequent impairment of the mitotic checkpoint in this leading cause of cancer deaths. As an initial step towards elucidation of the underlying mechanism, we further undertook a search for mutations in a key component of the mitotic checkpoint, known as hsMAD2, and its immediate downstream molecule, p55CDC. No such mutations were found, however, in either 21 lung cancer cell lines or 25 primary lung cancer cases, although we could identify silent polymorphisms and the transcribed and processed hsMAD2 pseudogene that was subsequently mapped at 14q21-q23. The present observations appear to warrant further investigations, such as search for alterations in other components, to better understand the molecular pathogenesis of this fatal disease, and warn against potential misinterpretation when performing mutational analyses for other cancer types based on cDNA templates.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B. . 1998 Science 282: 1497–1501.

  • Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JKV, Markowitz SD, Kinzler KW and Vogelstein B. . 1998 Nature 392: 300–303.

  • Chen RH, Waters JC, Salmon ED and Murray AW. . 1996 Science 274: 242–246.

  • Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH and Reid BJ. . 1995 Science 267: 1353–1356.

  • Elledge SJ. . 1998 Science 279: 999–1000.

  • Gotoh K, Yatabe Y, Sugiura T, Takagi K, Ogawa M, Takahashi T, Takahashi T and Mitsudomi T. . 1999 Carcinogenesis (in press).

  • Gualberto A, Aldape K, Kozakiewicz K and Tlsty TD. . 1998 Proc. Natl. Acad. Sci. USA 95: 5166–5171.

  • He X, Patterson TE and Sazer S. . 1997 Proc. Natl. Acad. Sci. USA 94: 7965–7970.

  • Hibi K, Yamakawa K, Ueda R, Horio Y, Murata Y, Tamari M, Uchida K, Takahashi T, Nakamura Y and Takahashi T. . 1994 Oncogene 9: 611–619.

  • Hoyt MA, Totis L and Roberts BT. . 1991 Cell 66: 507–517.

  • Hwang LH, Lau LF, Smith DL, Mistrot CA, Hardwick KG, Hwang ES, Amon A and Murray AW. . 1998 Science 279: 1041–1044.

  • Kim SH, Lin DP, Matsumoto S, Kitazono A and Matsumoto T. . 1998 Science 279: 1045–1047.

  • Kondo M, Suzuki H, Ueda R, Osada H, Takagi K, Takahashi T and Takahashi T. . 1995 Oncogene 10: 1193–1198.

  • Krishnan R, Goodman B, Jin DY, Jeang KT, Collins C, Stetten G and Spencer F. . 1998 Genomics 49: 475–478.

  • Lanni JS and Jacks T. . 1998 Mol. Cell. Biol. 18: 1055–1064.

  • Lengauer C, Kinzler KW and Vogelstein B. . 1997 Nature 386: 623–627.

  • Li R and Murray AW. . 1991 Cell 66: 519–531.

  • Li Y and Benezra R. . 1996 Science 274: 246–248.

  • Minna JD, Sekido Y, Fong KM and Gazdar AF. . 1997 In: Cancer Principles & Practice of Oncology, 5th edn, vol. 1. De Vita Jr VT, Hellman S and Rosenberg SA (eds).. Lippincott-Raven: Philadelphia. pp. 849–857.

    Google Scholar 

  • Paulovich AG, Toczyski DP and Hartwell LH. . 1997 Cell 88: 315–321.

  • Rudner AD and Murray AW. . 1996 Curr. Opin. Cell Biol. 8: 773–780.

  • Statistics and Information Department. . 1998 In: Vital Statistics of Japan 1996, Vol. 3. Ministry of Health and Welfare: Tokyo. pp. 384–411.

    Google Scholar 

  • Takahashi T, Ueda R, Song X, Nishida K, Shinzato M, Namikawa R, Ariyoshi Y, Ota K, Kato K, Nagatsu T, Imaizumi M, Abe T and Takahashi T. . 1986 Cancer Res. 46: 4770–4775.

  • Takahashi T, Nau M, Chiba I, Birrer M, Rosenberg R, Vinocour M, Levitt M, Pass H, Gazdar A and Minna J. . 1989 Science 246: 491–494.

  • Testa JR. . 1996 In: Lung Cancer: Principles and Practice. Pass HI, Mitchell JB, Johnson DH and Turrisi AT (eds).. Lippincott-Raven: Philadelphia. pp. 55–71.

    Google Scholar 

  • Weinstein J, Jacobsen FW, Hsu-Chen J, Wu T and Baum LG. . 1994 Mol. Cell. Biol. 14: 3350–3363.

Download references

Acknowledgements

We would like to thank R Ishida for his helpful suggestions and stimulating discussion. This work was supported in part by a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Science, Sport and Culture, Japan and a Grant-in-Aid for the Second Term Comprehensive Ten-Year Strategy for Cancer Control.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Takahashi, T., Haruki, N., Nomoto, S. et al. Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers. Oncogene 18, 4295–4300 (1999). https://doi.org/10.1038/sj.onc.1202807

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202807

Keywords

This article is cited by

Search

Quick links